The Valproate Neuroprotection Study is a Randomized, Double-Blind Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer’s Disease.
Pierre Tariot, M.D.
Background and Significance
This study represents a novel clinical trial strategy designed to assess both prospective “prophylactic” therapy for psychopathology in Alzheimer’s Disease (AD) and also to assess an approach that may alter several aspects of the pathophysiology of AD, thereby perhaps resulting in the alteration of clinical progression of illness. Interpretation of these results will be supported by the study of relevant biomarkers and imaging data.